[{"NetIncomeLoss_1_Q3_USD":842100000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":837400000.0,"OtherAssetsNoncurrent_0_Q3_USD":168800000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":1573000000.0,"Liabilities_0_Q3_USD":5958500000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":10900000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":-4900000.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"MarketableSecuritiesCurrent_0_Q3_USD":1452900000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0_Q3_USD":606000000.0,"LongTermDebtFairValue_0_Q3_USD":1929000000.0,"EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_0_Q3_USD":60600000.0,"InventoryFinishedGoodsNetOfReserves_0_Q3_USD":132100000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":30800000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":234400000.0,"AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_3_Q3_USD":-976900000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q3_USD":80900000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":800000.0,"AssetsCurrent_0_Q3_USD":9097600000.0,"MarketableSecuritiesRealizedGainLoss_3_Q3_USD":28500000.0,"OtherNoncashIncomeExpense_3_Q3_USD":111300000.0,"SellingGeneralAndAdministrativeExpense_3_Q3_USD":1042500000.0,"SellingGeneralAndAdministrativeExpense_1_Q3_USD":326900000.0,"FinanceLeaseLiabilityNoncurrent_0_Q3_USD":716500000.0,"ProceedsFromIssuanceOfLongTermDebt_3_Q3_USD":1981900000.0,"TreasuryStockShares_0_Q3_shares":15741824.0,"LossContingencyAccrualAtCarryingValue_0_Q3_USD":132200000.0,"StockIssuedDuringPeriodValueShareBasedCompensation_1_Q3_USD":297500000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":2373700000.0,"AccruedLiabilitiesAndOtherLiabilities_0_Q3_USD":1303000000.0,"IncreaseDecreaseInInventories_3_Q3_USD":402400000.0,"AccountsAndNotesReceivableNet_0_Q3_USD":486200000.0,"OtherOperatingIncomeExpenseNet_1_Q3_USD":44600000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":1990500000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":684600000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_0_Q3_USD":800000.0,"EarningsPerShareBasic_1_Q3_USD":7.98,"EarningsPerShareBasic_3_Q3_USD":21.83,"EquitySecuritiesFvNiUnrealizedGainLoss_3_Q3_USD":133800000.0,"EquitySecuritiesFvNiUnrealizedGainLoss_1_Q3_USD":-37500000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_3_Q3_shares":116100000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q3_shares":113900000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":218300000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":-28500000.0,"AccountsReceivableNetCurrent_0_Q3_USD":3092500000.0,"TreasuryStockValue_0_Q3_USD":6242000000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":221800000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0_Q3_USD":0.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3_Q3_USD":80800000.0,"TreasuryStockValueAcquiredCostMethod_1_Q3_USD":100400000.0,"AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_0_Q3_USD":2097500000.0,"DepreciationDepletionAndAmortization_3_Q3_USD":174200000.0,"EffectiveIncomeTaxRateContinuingOperations_3_Q3_pure":0.086,"EffectiveIncomeTaxRateContinuingOperations_1_Q3_pure":0.156,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":-1665200000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_0_Q3_USD":800000.0,"CostsAndExpenses_3_Q3_USD":3664600000.0,"CostsAndExpenses_1_Q3_USD":1240900000.0,"RestrictedCash_0_Q3_USD":13600000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_3_Q3_USD":3330300000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":156200000.0,"InventoryWorkInProcessNetOfReserves_0_Q3_USD":715400000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q3_USD":3550400000.0,"Assets_0_Q3_USD":16084000000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3_Q3_USD":652500000.0,"ProceedsFromShortTermDebt_3_Q3_USD":1500000000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":104600000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":1387100000.0,"InventoryRawMaterialsNetOfReserves_0_Q3_USD":400400000.0,"WeightedAverageNumberOfSharesOutstandingBasic_3_Q3_shares":108300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q3_shares":105500000.0,"PaymentsToAcquireProductiveAssets_3_Q3_USD":453200000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0_Q3_USD":1452900000.0,"MarketableSecuritiesNoncurrent_0_Q3_USD":2875100000.0,"RepaymentsOfShortTermDebt_3_Q3_USD":1500000000.0,"LiabilitiesCurrent_0_Q3_USD":2337800000.0,"NonoperatingIncomeExpense_3_Q3_USD":176200000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":42900000.0,"NonoperatingIncomeExpense_1_Q3_USD":-54800000.0,"InterestExpense_1_Q3_USD":26300000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":1586600000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":230600000.0,"LongTermDebtNoncurrent_0_Q3_USD":1978300000.0,"IncreaseDecreaseInDeferredIncomeTaxes_3_Q3_USD":-117900000.0,"AccountsPayableCurrentAndNoncurrent_0_Q3_USD":443100000.0,"AdditionalPaidInCapital_0_Q3_USD":6592800000.0,"DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0_Q3_USD":606000000.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"CapitalExpendituresIncurredButNotYetPaid_3_Q3_USD":100400000.0,"OtherInventoryNetOfReserves_0_Q3_USD":553700000.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":3138300000.0,"NetIncomeLoss_3_Q3_USD":2364000000.0,"InterestExpense_3_Q3_USD":42100000.0,"OtherOperatingIncomeExpenseNet_3_Q3_USD":135200000.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":2642700000.0,"EarningsPerShareDiluted_3_Q3_USD":20.36,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":-4700000.0,"ShareBasedCompensation_3_Q3_USD":310500000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.01,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":2471100000.0,"DeferredIncomeTaxAssetsNet_0_Q3_USD":804200000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":-16400000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":6074200000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":2294000000.0,"OperatingIncomeLoss_3_Q3_USD":2409600000.0,"OperatingIncomeLoss_1_Q3_USD":1053100000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3_Q3_USD":2585800000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q3_USD":998300000.0,"PaymentsForRepurchaseOfCommonStock_3_Q3_USD":5465700000.0,"EarningsPerShareDiluted_1_Q3_USD":7.39,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_3_Q3_USD":-1200000.0,"InventoryNet_0_Q3_USD":1801600000.0,"PreferredStockValue_0_Q3_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":16084000000.0,"PreferredStockSharesAuthorized_0_Q3_shares":30000000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0_Q3_USD":0.0,"OtherLiabilitiesNoncurrent_0_Q3_USD":454000000.0,"OtherLiabilitiesCurrent_0_Q3_USD":96900000.0,"StockholdersEquity_0_Q3_USD":10125500000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":3508300000.0,"AccountsReceivableRelatedPartiesCurrent_0_Q3_USD":460800000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":9743800000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":-43700000.0,"IncreaseDecreaseInAccountsReceivable_3_Q3_USD":1275300000.0,"OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1_Q3_USD":200000.0,"IncreaseDecreaseInContractWithCustomerLiability_3_Q3_USD":112300000.0,"Ticker":"REGN","CIK":"872589","name":"REGENERON PHARMACEUTICALS, INC.","OfficialName":"Regeneron Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"77738004554.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"SP500","filed":"20201105"}]